Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q2 FY23 results · Jul–Sep 2022
Ajanta Pharma reported revenue from operations of ₹938.10 crore (up 6.0% from Q2 FY22) and net profit of ₹156.60 crore (down 20.1% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 938.10 | 884.80 | +6.0% | 950.93 | −1.3% |
| Other income | 40.35 | 29.54 | +36.6% | 32.76 | +23.2% |
| Total income | 978.45 | 914.34 | +7.0% | 983.69 | −0.5% |
| Profit before tax | 203.00 | 260.42 | −22.0% | 221.86 | −8.5% |
| Net profit for the period | 156.60 | 195.94 | −20.1% | 174.62 | −10.3% |
| EPS, basic (₹) | 12.22 | 22.64 | not comparable | 13.63 | −10.3% |
| Net margin (%) | 16.7 | 22.1 | 18.4 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 837.23 | 823.71 | +1.6% | 850.29 | −1.5% |
| Other income | 78.37 | 52.41 | +49.5% | 35.42 | +121.3% |
| Total income | 915.60 | 876.12 | +4.5% | 885.71 | +3.4% |
| Profit before tax | 206.59 | 254.79 | −18.9% | 190.35 | +8.5% |
| Net profit for the period | 167.18 | 196.85 | −15.1% | 150.37 | +11.2% |
| EPS, basic (₹) | 13.05 | 22.75 | not comparable | 11.74 | +11.2% |
| Net margin (%) | 20.0 | 23.9 | 17.7 |
Consolidated
- Filed with BSE
- 04 Nov 2022, 15:08 IST
- Board meeting
- 03 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Nov 2022, 15:08 IST
- Board meeting
- 03 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE